This triplet study is an IST so USCF will be paying for it. More inportantly is that Merck is very interested in testing TAVO in expanded combinations. They are obviously very interested in the potential Oncosec has. Duke University will be starting pre-clinical work with TAVO in combo with vaccines. The future for Keytruda expansion will be combo therapie. TAVO will eventually be targeting frontline therapy. All we need is PISCES to get an AA next year and Oncosec's platform will be validated....Merck will know the FDA is willing to give the thumbs up for TAVO. Green sky ahead for those who care to hang in here.
News 
Market Data 
Discover 
AI
